GlassScriptPhysician profile
Ralph Taguba
NPI 1881164739
$2,313.40
in general payments reported to CMS, 2019-2025
21 companies · $963 in 2025
The $963 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $321 · 2024: $1,029 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.41 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $413.29 | 2023-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $279.93 | 2023-2025 | |
| Novo Nordisk INC | $224.52 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $209.99 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $208.40 | 2024-2025 | |
| Glaxosmithkline, LLC. | $168.16 | 2023-2025 | Shingrix, Bexsero, Pediarix |
| Exact Sciences Corporation | $133.87 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.59 | 2024-2025 | Jardiance |
| Sanofi Pasteur INC. | $78.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.59 | 2024-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $56.12 | 2024 | Spravato |
| Viiv Healthcare Company | $53.48 | 2025 | Apretude |
| Boston Scientific Corporation | $53.40 | 2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Mylan Specialty L.P. | $49.22 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $42.09 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $41.51 | 2024-2025 | |
| Edwards Lifesciences Corporation | $32.04 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Aimmune Therapeutics, INC. | $29.70 | 2024 | |
| Madrigal Pharmaceuticals | $28.76 | 2025 | Rezdiffra |
| Exeltis, USA INC. | $24.06 | 2025 | Slynd |
| Organon LLC | $15.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Taguba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.